Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01777464
Other study ID # september2012
Secondary ID
Status Terminated
Phase N/A
First received January 23, 2013
Last updated December 2, 2015
Start date November 2012
Est. completion date March 2016

Study information

Verified date September 2014
Source Universitaire Ziekenhuizen Leuven
Contact n/a
Is FDA regulated No
Health authority Belgium: Federal Agency for Medicinal Products and Health Products
Study type Interventional

Clinical Trial Summary

In order to evaluate the effects a nasal provocation on the activation of different brain regions, the investigators want to set up a clinical trial investigating the short-term effects of a nasal histamine provocation in healthy volunteers and allergic patients while in supine position under the functional MRI device in order to visualize different brain regions.


Description:

Evaluate the effects a nasal provocation on the activation of different brain regions


Recruitment information / eligibility

Status Terminated
Enrollment 14
Est. completion date March 2016
Est. primary completion date February 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Patients with a positive skin prick test to grass pollen and with pollen allergic symptoms during the pollen season OR patients with a negative skin prick test and with no allergic symptoms during the pollen season.

- Age > 18 and < 50 years

- Written informed consent

- Willingness to adhere to visit schedules

- Adequate contraceptive precautions in female patients with childbearing potential

Exclusion Criteria:

- Current or recent (finished less than 2 years) immunotherapy against grass pollen.

- Systemic steroid treatment less than 6 weeks before the inclusion in the study.

- Nasal steroid spray, oral leukotriene antagonists or long-acting antihistamines less than 4 weeks before the inclusion.

- Presence of purulent secretions in nasal cavity.

- Severe septal deviation (septum reaching concha inferior or lateral nasal wall).

- Patient is pregnant or breastfeeding.

- Patient has any disorder of which the investigators feel at the time of evaluation for participation in the study that this may compromise the ability to give truly informed consent for participation in this study.

- Patient is currently enrolled in other investigational drug trial(s) or is receiving other investigational agent(s) for any other medical condition.

- No independent medication management in daily life or disability to perform fine motoric handling of medication

- Patients with asthma will be excluded.

- Patients suffering from claustrophobia

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Biological:
histamine
administration of histamine solution (16 mg/ml) via aerosol for 5 minutes while lying under a fMRI scan
sham
sham solution

Locations

Country Name City State
Belgium uz leuven ORL Leuven Vlaams Brabant

Sponsors (1)

Lead Sponsor Collaborator
Universitaire Ziekenhuizen Leuven

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary brain activation The specific aim of this study is to visualize the type and location of brain activation in healthy and allergic volunteers by a nasal provocation with histamine, using the functional MRI technology. 5 minutes No
Secondary nasal symptoms and Peak Nasal Inspiratory Flow Evaluation of nasal symptoms (runny nose, blocked nose, itchy nose and post-nasal drip) and conjunctival symptoms (lacrimation and itchy eyes) will be done with VAS scores and the Peak Nasal Inspiratory Flow (PNIF) will be measured before and after both functional MRI (fMRI) scans before and after scans No
See also
  Status Clinical Trial Phase
Completed NCT02443805 - Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR Phase 3
Completed NCT03094845 - Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients Phase 2
Completed NCT01923792 - ToleroMune House Dust Mite Follow on Study N/A
Completed NCT01930461 - Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma Phase 2
Completed NCT00574704 - A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis Phase 2
Completed NCT00263549 - Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis Phase 4
Completed NCT05019209 - Skin Responses and T Cell Immunology After House Dust Mite Exposure in Sensitized Atopic Dermatitis Patients N/A
Recruiting NCT02238353 - AZELASTINE/FLUTICASONE (AZE/FLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR) Phase 4
Completed NCT01454544 - A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet Phase 3
Completed NCT00574223 - A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis Phase 2
Completed NCT02345278 - SUBLIVAC FIX Mite Mixture Dose Tolerability Study Phase 1/Phase 2
Completed NCT01608243 - Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts Phase 1
Completed NCT04435678 - Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens N/A
Completed NCT01134757 - Safety of Bronchial Allergen Challenge and Predictors for Positive Reaction. N/A
Recruiting NCT05395689 - Efficacy and Safety Assessment of Beltavac® With Polymerized Extract of HDM Phase 3
Not yet recruiting NCT05400811 - Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis Phase 3
Not yet recruiting NCT05450289 - The Efficacy of Nigella Sativa in Children With House Dust Mite-Induced Respiratory Allergy Receiving Immunotherapy N/A
Recruiting NCT05174689 - Epigenetic Regulation of Exercise Induced Asthma N/A
Terminated NCT04874714 - Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis Phase 3
Completed NCT00380926 - Fish Oil and Asthma in House Dust Mite Allergy Phase 2/Phase 3